EUVIMEDEUVIMED entdecken
Crossref

Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process

Xiaoyun Ding, Xue Han, Yue Zhang, Yan Zhang, Fengmei Li, Jing Wang iD

Journal of Biochemical and Molecular Toxicology · 2025

DOI: 10.1002/jbt.70565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Xiaoyun Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Hospital, General Hospital of Ningxia Medical University, Yinchuan, China. Hauptthemen laut MEDLINE: Cisplatin, Saponins, NF-E2-Related Factor 2, Triterpenes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: This study was funded by the Natural Science Foundation of Ningxia (Grant Nos. 2021AAC03144 and 2023AAC03245)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High incidence of nephrotoxicity poses a significant hurdle to the clinical utility of cisplatin (CDDP), which profoundly impacts the efficacy of chemotherapy. Astragaloside IV (AS‐IV) is a characteristic saponin component of Astragalus membranaceus , known for its antioxidant and anti‐inflammatory properties. However, the precise role of AS‐IV in the context of CDDP chemotherapy remains elusive. Herein, we unveil AS‐IV's capability to alleviate CDDP‐induced nephrotoxicity in Lewis lung carcinoma mice and renal tubular epithelial cells (RTECs). This is achieved by upregulating antioxidant enzymes, activating Nrf2/HO‐1 pathway, while concurrently suppressing release of pro‐inflammatory cytokines and inhibiting p‐NF‐κB(p65) expression. Furthermore, our research reveals the anti‐fibrosis ability of AS‐IV on RTECs induced by inflammatory mediators TNF‐α and TGF‐β1 through reversal of the epithelial‐mesenchymal transformation (EMT) process. These findings not only suggest the viable potential of AS‐IV in combination with CDDP to alleviate nephrotoxicity, but also underscore its medicinal promise in enhancing chemotherapy effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinSaponinsNF-E2-Related Factor 2TriterpenesEpithelial-Mesenchymal TransitionHeme Oxygenase-1Signal TransductionNF-kappa BKidney DiseasesMembrane ProteinsAntineoplastic AgentsAnimalsMiceMice, Inbred C57BLMaleCarcinoma, Lewis LungEpithelial Cells

Stichwörter der Autor:innen

Astragaloside IVNrf2/NF‐κBcisplatinepithelial‐mesenchymal transformationnephrotoxicity

Substanzen

CisplatinSaponinsastragaloside ANF-E2-Related Factor 2TriterpenesNfe2l2 protein, mouseHeme Oxygenase-1Hmox1 protein, mouseNF-kappa BMembrane Proteins

Autor:innen und Institutionen

  • Oncology Hospital, General Hospital of Ningxia Medical University, Yinchuan, China.
  • School of Pharmacy, Ningxia Medical University, Yinchuan, China.

ORCID-Profile: Jing Wang

Förderung

  • This study was funded by the Natural Science Foundation of Ningxia (Grant Nos. 2021AAC03144 and 2023AAC03245).

Zitieren

APA

Ding, X., Han, X., Zhang, Y., Zhang, Y., Li, F., & Wang, J. (2025). Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70565

Vancouver

Ding X, Han X, Zhang Y, Zhang Y, Li F, Wang J. Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70565

BibTeX
@article{Ding2025,
  author = {Ding, Xiaoyun and Han, Xue and Zhang, Yue and Zhang, Yan and Li, Fengmei and Wang, Jing},
  title = {Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2025},
  doi = {10.1002/jbt.70565}
}
Kostenlos starten →